MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, is an ultra rapid-acting insulin that has completed Phase III clinical trials evaluating its safety and efficacy in the treatment of diabetes. AFRESA consists of the Company’s Technosphere particles, onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled deep into the lung using the Company’s AFRESA inhaler.